Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Fineline Cube Apr 30, 2026
Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Fineline Cube Apr 30, 2026
Company Drug

EMA Panel Recommends Bio-Thera’s Usymro for Autoimmune Diseases

Fineline Cube Jun 23, 2025

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Drug

J&J’s Darzalex SC Recommended by CHMP for High-Risk Smoldering Multiple Myeloma

Fineline Cube Jun 23, 2025

The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended...

Company Drug

Eli Lilly’s Efsitora Meets Key Endpoints in Phase III Trials for Type 2 Diabetes

Fineline Cube Jun 23, 2025

US major Eli Lilly and Company (NYSE: LLY) presented detailed results from the Phase III...

Company Drug

Johnson & Johnson’s Imbruvica Secures CHMP Recommendation for Expanded MCL Use

Fineline Cube Jun 23, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that the Committee for Medicinal Products...

Company Drug

Bayer’s Nubeqa Receives Positive CHMP Opinion for mHSPC Treatment

Fineline Cube Jun 23, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced last week that the European Medicines Agency...

Company Deals

Boao Lecheng Partners with China National Center for Neurological Diseases to Establish Translational Center

Fineline Cube Jun 23, 2025

The Boao Lecheng International Medical Tourism Pilot Zone Administration announced last week a strategic cooperation...

Company Drug

Sichuan Huiyu’s CDCP1-Targeted ADC HY0001a Gets NMPA Clinical Trial Approval

Fineline Cube Jun 23, 2025

China-based Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553) announced that it has received clinical trial...

Company Drug

Changshan Biochemical Receives NMPA Clearance for Albenatide in Weight Loss Trials

Fineline Cube Jun 23, 2025

China’s Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255) announced that it has received...

Company Drug

ImmuneOnco Receives NMPA Approval for IMC-003/IMM72 in Pulmonary Arterial Hypertension Trial

Fineline Cube Jun 23, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced that it has received clinical trial...

Company Deals

United Imaging Intelligence Closes RMB 1B Series A Round to Boost AI in Healthcare

Fineline Cube Jun 23, 2025

United Imaging Intelligence, the AI-focused subsidiary of Shanghai United Imaging Healthcare Co., Ltd., reportedly secured...

Company Medical Device

MGI Tech’s DNBSEQ-T1+ Gains CE IVDR Certification for EU Market Entry

Fineline Cube Jun 23, 2025

China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) announced that its latest mid-throughput...

Company Deals

Jiangxi Rimag to Acquire 70% Stake in Guangzhou Gaomai for RMB 54 Million

Fineline Cube Jun 23, 2025

China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) is set to acquire a 70% stake...

Company Drug

Simcere Pharma’s Quviviq Receives NMPA Approval for Insomnia Treatment

Fineline Cube Jun 23, 2025

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) revealed that its marketing approval filing for Quviviq...

Company Drug

Sanofi and Regeneron Win FDA Approval for Dupixent in Bullous Pemphigoid Treatment

Fineline Cube Jun 23, 2025

France major Sanofi (NASDAQ: SNY) and US-based biopharma Regeneron (NASDAQ: REGN) announced that Dupixent (dupilumab)...

Company Drug

Zai Lab’s Partner argenx Secures EU Approval for Vygart in CIDP Treatment

Fineline Cube Jun 23, 2025

China-based Zai Lab Limited’s (NASDAQ: ZLAB, HKG: 9688) Dutch partner argenx SE (NASDAQ: ARGX) announced...

Company Deals

Harbour BioMed and Otsuka Pharma Collaborate Globally on BCMAxCD3 Bispecific T-cell Engager

Fineline Cube Jun 23, 2025

China-based Harbour BioMed (HKG: 2142) has entered into a global strategic collaboration with Japan-headquartered Otsuka...

Company Drug

CanSino Biologics’ PCV13i Vaccine Gains NMPA Approval

Fineline Cube Jun 23, 2025

China-based CanSino Biologics Inc., (HKG: 6185) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Zhongsheng Pharma’s RAY1225 Enters Phase III Trial for Obesity/Overweight Treatment

Fineline Cube Jun 20, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the initiation of the multi-center, randomized,...

Company Drug

Dizal’s Phase III Trial Completes Enrollment for Shuwozhe in EGFR Exon20ins NSCLC

Fineline Cube Jun 20, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the completion of patient enrollment for its...

Company Drug

Shanghai Pharmaceuticals Receives Thai FDA Approval for Pregabalin Capsules

Fineline Cube Jun 20, 2025

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that it has...

Posts pagination

1 … 133 134 135 … 660

Recent updates

  • BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer
  • Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength
  • Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer
  • Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam
  • AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Company

Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.